CVS vs. GILD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CVS and GILD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CVS | GILD |
|---|---|---|
| Company Name | CVS Health Corporation | Gilead Sciences, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 97.50 billion USD | 139.28 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | February 21, 1973 | January 22, 1992 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CVS and GILD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CVS | GILD |
|---|---|---|
| 5-Day Price Return | 3.03% | 0.14% |
| 13-Week Price Return | 10.48% | -0.52% |
| 26-Week Price Return | 13.73% | -0.01% |
| 52-Week Price Return | 22.25% | 32.57% |
| Month-to-Date Return | 1.96% | 0.14% |
| Year-to-Date Return | 71.24% | 20.33% |
| 10-Day Avg. Volume | 7.56M | 8.40M |
| 3-Month Avg. Volume | 7.55M | 7.10M |
| 3-Month Volatility | 27.58% | 28.15% |
| Beta | 0.48 | 0.34 |
Profitability
Return on Equity (TTM)
CVS
5.95%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
CVS’s Return on Equity of 5.95% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
GILD
32.97%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, GILD’s Return on Equity of 32.97% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
CVS
1.17%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
CVS’s Net Profit Margin of 1.17% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
GILD
21.87%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 21.87% places GILD in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
CVS
2.44%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
CVS’s Operating Profit Margin of 2.44% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
GILD
27.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 27.89% places GILD in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | CVS | GILD |
|---|---|---|
| Return on Equity (TTM) | 5.95% | 32.97% |
| Return on Assets (TTM) | 1.78% | 11.19% |
| Net Profit Margin (TTM) | 1.17% | 21.87% |
| Operating Profit Margin (TTM) | 2.44% | 27.89% |
| Gross Profit Margin (TTM) | 13.82% | 78.53% |
Financial Strength
Current Ratio (MRQ)
CVS
0.80
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
CVS’s Current Ratio of 0.80 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
GILD
1.32
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
GILD’s Current Ratio of 1.32 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
CVS
0.86
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
CVS’s Debt-to-Equity Ratio of 0.86 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
GILD
1.27
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
GILD’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 1.27. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
CVS
3.08
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
CVS’s Interest Coverage Ratio of 3.08 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
GILD
1.71
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
GILD’s Interest Coverage Ratio of 1.71 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | CVS | GILD |
|---|---|---|
| Current Ratio (MRQ) | 0.80 | 1.32 |
| Quick Ratio (MRQ) | 0.62 | 0.89 |
| Debt-to-Equity Ratio (MRQ) | 0.86 | 1.27 |
| Interest Coverage Ratio (TTM) | 3.08 | 1.71 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CVS
3.54%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.54%, CVS offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
GILD
4.23%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GILD’s Dividend Yield of 4.23% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio (TTM)
CVS
74.62%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
CVS’s Dividend Payout Ratio of 74.62% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
GILD
117.08%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 117.08%, GILD’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | CVS | GILD |
|---|---|---|
| Dividend Yield (TTM) | 3.54% | 4.23% |
| Dividend Payout Ratio (TTM) | 74.62% | 117.08% |
Valuation
Price-to-Earnings Ratio (TTM)
CVS
21.10
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
CVS’s P/E Ratio of 21.10 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
GILD
22.21
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
GILD’s P/E Ratio of 22.21 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
CVS
0.25
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
In the lower quartile for the Health Care Providers & Services industry, CVS’s P/S Ratio of 0.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
GILD
4.86
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
GILD’s P/S Ratio of 4.86 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
CVS
1.13
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
CVS’s P/B Ratio of 1.13 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
GILD
7.01
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
GILD’s P/B Ratio of 7.01 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | CVS | GILD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.10 | 22.21 |
| Price-to-Sales Ratio (TTM) | 0.25 | 4.86 |
| Price-to-Book Ratio (MRQ) | 1.13 | 7.01 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.43 | 15.35 |